J&J Subsidiary To Apply For Japan Approval of Intelence AIDS Drug
This article was originally published in PharmAsia News
Executive Summary
Janssen Pharmaceutical says it plans to apply for Japanese approval of its TMC125 (etravine) anti-retroviral for treating AIDS. The drug is sold in the United States as Intelence by Janssen's parent, Johnson & Johnson. If approved, it would be one of only a few of its type marketed in Japan. Janssen plans to apply to market the drug as a treatment for HIV patients resistant to other drugs or who have experienced a resurgence of the virus after treatment with other drugs. In the future, Janssen plans to get TMC125 approved as a first-choice combination treatment. (Click here for more - a subscription may be required